VA-ECMO – Medxy AI

Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT

By MedXY 12/12/2025

A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarkers of gut, renal, hepatic injury or inflammation.

Cardiology Critical Care news

VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock

By MedXY 12/09/2025

A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.

Cardiology Critical Care news

Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial

By MedXY 12/09/2025

In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.

Cardiology Specialties

Long-Term Functional Recovery and Survival after VA-ECMO: Insights from a 26-Center Prospective Cohort Study

By MedXY 08/17/2025

A multicenter study reveals that 30% of adult VA-ECMO patients survive 12 months without new disability, with most disability developing within the first 6 months. Functional independence and employment improve by 12 months post-ECMO.